Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Axsome Therapeutics

Axsome Therapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating

Axsome Therapeutics sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

Stocks Flashing Renewed Technical Strength: Axsome Therapeutics

Axsome Therapeutics sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

This Little-Known Stock Could Be One of the Best Recession-Proof Investments Now

RBC flags this biopharma stock as recession-ready, with stellar upside potential hiding in plain sight.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.

Investors Business Daily

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

Axsome stock tumbled Tuesday after Axsome Therapeutics issued mixed results for its drug, Sunosi, in ADHD treatment.

Investors Business Daily

Axsome Therapeutics Clears Technical Benchmark, Hitting 90-Plus RS Rating

Axsome Therapeutics sees its Relative Strength Rating reach the elite 90-plus level.

Investors Business Daily

Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation

Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

IBD Rating Upgrades: Axsome Therapeutics Flashes Improved Technical Strength

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. Will it continue?

Investors Business Daily

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.

Benzinga

Stocks Showing Rising Market Leadership: Axsome Therapeutics Earns 83 RS Rating

Axsome Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 83.

Investors Business Daily

Stocks Showing Rising Market Leadership: Axsome Therapeutics Earns 82 RS Rating

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 66 to 82.

Investors Business Daily

Axsome Therapeutics Trying To Close In On Key Technical Measure

Axsome Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

IBD Rating Upgrades: Axsome Therapeutics Shows Improved Relative Price Strength

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. Will it continue?

Investors Business Daily

Stocks Generating Improved Relative Strength: Axsome Therapeutics

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. Will it continue?

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Investors Business Daily

Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Investors Business Daily

Axsome Therapeutics Expects Up To $11.5 Billion In Peak Sales, Wallops Analysts' Forecasts

Axsome expects its eight products to generate up to $11.5 billion in peak U.S. sales. AXSM stock zoomed higher Wednesday.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Dips As Zscaler Rockets; Three Warren Buffett Stocks Near Entries As Berkshire Gains

The Dow Jones was flat. Disney stock rose amid further escalation in its Ron DeSantis fight. A trio of Warren Buffett stocks neared entries.

Investors Business Daily

Highly Rated Axsome Surges On Earnings Beat. And Here's Why BioXcel Reversed.

Axsome and BioXcel issued divergent earnings reports Monday, but BTAI stock reversed an earlier dive and rose alongside AXSM stock.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Royal Caribbean Cruises

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.